UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon"s PEGylation technology, including PEG-INTRON®, Macugen®, and Pegasys®.
Public Health
Pages: 1 [2]
What Is Dyspraxia? How Is Dyspraxia Treated?
say, holding on tight, and correcting themselves. Parents who have a child with dyspraxia need to balance the risks of negative things happening outside, with the enormous benefits that active play has to offer. Deciding what this balance is depends on many factors, such as the severity of the child"s dyspraxia, the outside environment, etc. A study by researchers at the University of North Carolina at Chapel Hill"s Frank Porter Graham (FPG) Child Development Institute and UNC"s School of Education indicates that if both parents work, the father"s influence on a very young child"s language development may be greater than previously thought (not specific to dyspraxia, but interesting from a child development point of view) Written by Christian Nordqvist Copyright: Medical News Today Not to be reproduced without permission of Medical News TodayPages: 1 [2]